Mono Clinical Trials

166 recruitingLast updated: May 13, 2026

There are 166 actively recruiting mono clinical trials across 37 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, Boston, Massachusetts, United States, Seattle, Washington, United States. Updated daily from ClinicalTrials.gov.


Mono Trials at a Glance

166 actively recruiting trials for mono are listed on ClinicalTrialsFinder across 6 cities in 37 countries. The largest study group is Phase 2 with 65 trials, with the heaviest enrollment activity in Houston, Boston, and Seattle. Lead sponsors running mono studies include M.D. Anderson Cancer Center, Fred Hutchinson Cancer Center, and Mayo Clinic.

Treatments under study

About Mono Clinical Trials

Looking for clinical trials for Mono? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Mono trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Mono clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 166 trials

Recruiting

Study of Factors Regulating Mast Cell Proliferation

MastocytosisMonoclonalBone Marrow+1 more
National Institute of Allergy and Infectious Diseases (NIAID)600 enrolled1 locationNCT00044122
Recruiting
Phase 1

Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

EBVEpstein-Barr Virus InfectionInfectious Mononucleosis+1 more
National Institute of Allergy and Infectious Diseases (NIAID)750 enrolled1 locationNCT06908096
Recruiting
Phase 1Phase 2

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Smoldering Multiple MyelomaMyelodysplastic SyndromesWaldenstrom Macroglobulinemia+5 more
Dana-Farber Cancer Institute10,000 enrolled7 locationsNCT02269592
Recruiting
Phase 1Phase 2

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome+5 more
PedAL BCU, LLC960 enrolled183 locationsNCT04726241
Recruiting

National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases

AniridiaAlbinismCorneal Dystrophy+4 more
National Eye Institute (NEI)1,000 enrolled2 locationsNCT06491615
Recruiting
Not Applicable

VisionApp - Ghosting

Diplopia, Monocular
Indiana University12 enrolled1 locationNCT07571538
Recruiting

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Small Lymphocytic LymphomaWaldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma+2 more
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT00923507
Recruiting
Phase 2

Methods of T Cell Depletion Trial (MoTD)

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHodgkin Lymphoma+6 more
University of Birmingham400 enrolled17 locationsNCT04888741
Recruiting
Phase 2Phase 3

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+1 more
Taiho Oncology, Inc.316 enrolled71 locationsNCT04256317
Recruiting
Phase 2

Personalized NK Cell Therapy in CBT

Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia+23 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02727803
Recruiting
Phase 1

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Acute Myeloid LeukemiaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+10 more
Newave Pharmaceutical Inc100 enrolled8 locationsNCT04771572
Recruiting

Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood

Myelodysplastic SyndromesJuvenile Myelomonocytic Leukemia
University Hospital Freiburg260 enrolled1 locationNCT00662090
Recruiting
Phase 1Phase 2

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Hematopoietic and Lymphoid Cell NeoplasmAcute Myeloid Leukemia in RemissionChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT03670966
Recruiting
Not Applicable

FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
University of Miami120 enrolled1 locationNCT07446777
Recruiting
Phase 2

Glucokinase Activator in Monogenic Diabetes

Diabetes MellitusMonogenic Diabetes
Chinese University of Hong Kong44 enrolled1 locationNCT06976658
Recruiting

Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution

Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)Multiple Myeloma (MM)
Azienda USL Reggio Emilia - IRCCS60 enrolled4 locationsNCT07214324
Recruiting

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Plasma Cell Myeloma
M.D. Anderson Cancer Center200 enrolled1 locationNCT02726750
Recruiting
Phase 1

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Recurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Myelodysplastic SyndromeRecurrent Juvenile Myelomonocytic Leukemia+3 more
Children's Oncology Group36 enrolled19 locationsNCT06247787
Recruiting
Phase 2

Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance

IgA Monoclonal Gammopathy of Undetermined Significance
Fred Hutchinson Cancer Center50 enrolled1 locationNCT07209371